Cargando…

Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors

BACKGROUND: Coronavirus disease 2019 (COVID‐19) is associated with high rates of thromboembolic events in hospitalized patients. It remains to be determined if this risk persists following hospital discharge. METHODS: We conducted a retrospective cohort study of outpatients recently hospitalized for...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eswaran, Harish, Jarmul, Jamie A., Shaheen, Amy W., Meaux, David, Long, Tristan, Saccoccio, Derek, Moll, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles ‐ Thrombosis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7938613/ https://www.ncbi.nlm.nih.gov/pubmed/33733027 http://dx.doi.org/10.1002/rth2.12485

Ejemplares similares

Incidence of Vascular Thromboembolic Events in Outpatients with Mild COVID-19
por: Eswaran, Harish, et al.
Publicado: (2020)

Risk of recurrence in women with venous thromboembolism related to estrogen‐containing contraceptives: Systematic review and meta‐analysis
por: Wiegers, Hanke M. G., et al.
Publicado: (2022)

Genetic risk and incident venous thromboembolism in middle‐aged and older adults following COVID‐19 vaccination
por: Xie, Junqing, et al.
Publicado: (2022)

Cancer‐associated venous thromboembolism: Incidence and features in a racially diverse population
por: Raskob, Gary E., et al.
Publicado: (2022)

Elevated plasma levels of plasminogen activator inhibitor‐1 are associated with risk of future incident venous thromboembolism
por: Frischmuth, Tobias, et al.
Publicado: (2022)

Overall and abdominal obesity in relation to venous thromboembolism
por: Yuan, Shuai, et al.
Publicado: (2020)

Joint effect of myocardial infarction and obesity on the risk of venous thromboembolism: The Tromsø Study
por: Sejrup, Joakim K., et al.
Publicado: (2022)

Incidence of symptomatic, image-confirmed venous thromboembolism following hospitalization for COVID-19 with 90-day follow-up
por: Salisbury, Richard, et al.
Publicado: (2020)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Hematocrit and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2020)

Clinical characteristics and outcomes of incidental venous thromboembolism in cancer patients: Insights from the Caravaggio study
por: Giustozzi, Michela, et al.
Publicado: (2021)

D‐dimer to rule out venous thromboembolism during pregnancy: A systematic review and meta‐analysis
por: Bellesini, Marta, et al.
Publicado: (2021)

Pharmacokinetic modeling and simulation support for age‐ and weight‐adjusted dosing of dabigatran etexilate in children with venous thromboembolism
por: Röshammar, Daniel, et al.
Publicado: (2021)

Dynamic assessment of venous thromboembolism risk in patients with cancer by longitudinal D‐Dimer analysis: A prospective study
por: Posch, Florian, et al.
Publicado: (2020)

Risk scores for occult cancer in patients with unprovoked venous thromboembolism: Results from an individual patient data meta‐analysis
por: Mulder, Frits I., et al.
Publicado: (2020)

Awareness of venous thromboembolism among patients with cancer: Preliminary findings from a global initiative for World Thrombosis Day
por: Potere, Nicola, et al.
Publicado: (2022)

Thromboembolic events, bleeding, and mortality in patients with cerebral venous thrombosis: a nationwide cohort study
por: Skajaa, Nils, et al.
Publicado: (2022)

Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta‐analysis
por: Horner, Daniel, et al.
Publicado: (2019)

Resting heart rate and incidence of venous thromboembolism
por: Folsom, Aaron R., et al.
Publicado: (2019)

The risk of arterial thromboembolic events after cancer diagnosis
por: Navi, Babak B., et al.
Publicado: (2019)

Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma
por: Kaptein, Fleur H. J., et al.
Publicado: (2022)

Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery—Systematic review and meta‐analysis
por: Presume, João, et al.
Publicado: (2022)

Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement
por: Jameson, S. S., et al.
Publicado: (2014)

The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study
por: Driever, Ellen G., et al.
Publicado: (2022)

Vascular thromboembolic events following COVID‐19 hospital discharge: Incidence and risk factors
por: Spyropoulos, Alex C., et al.
Publicado: (2021)

Associations of coagulation factor X and XI with incident acute coronary syndrome and stroke: A nested case‐control study
por: Chen, Huiting, et al.
Publicado: (2021)

Galectin‐3 and venous thromboembolism incidence: the Atherosclerosis Risk in Communities (ARIC) Study
por: Fashanu, Oluwaseun E., et al.
Publicado: (2017)

Impact of respiratory symptoms and oxygen saturation on the risk of incident venous thromboembolism—the Tromsø study
por: Børvik, Trond, et al.
Publicado: (2020)

Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
por: Berkowitz, Scott D., et al.
Publicado: (2022)

Thromboembolic Outcomes of Hospitalized COVID-19 Patients in the 90-Day Post-Discharge Period: Early Data from the Northwell CORE-19 Registry
por: Giannis, Dimitrios, et al.
Publicado: (2020)

Frequency of venous thromboembolism in 6513 patients with COVID-19: a retrospective study
por: Hill, Jason B., et al.
Publicado: (2020)

Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study
por: Carney, Brian J., et al.
Publicado: (2021)

Comparison of thromboembolism outcomes in patients with sickle cell disease prescribed hormonal contraception
por: Bala, Natasha S., et al.
Publicado: (2023)

Polygenic risk of major depressive disorder as a risk factor for venous thromboembolism
por: Ward, Joey, et al.
Publicado: (2023)

Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: the CORE-19 registry
por: Giannis, Dimitrios, et al.
Publicado: (2021)

Predicting major bleeding during extended anticoagulation for unprovoked or weakly provoked venous thromboembolism
por: Wells, Philip S., et al.
Publicado: (2022)

First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men
por: Nowotny, Bettina, et al.
Publicado: (2022)

Breast cancer cells mediate endothelial cell activation, promoting von Willebrand factor release, tumor adhesion, and transendothelial migration
por: Dhami, Sukhraj Pal Singh, et al.
Publicado: (2022)

Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy
por: Overvad, Thure Filskov, et al.
Publicado: (2022)

Venous thromboembolism prophylaxis in sickle cell disease: a multicenter cohort study of adolescent inpatients
por: Davila, Jennifer, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ssia5v7d5o0nfje5bftmglf7so